A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2

Summary

The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.

Timeline

Start

2024-07-26

Primary completion

2025-11-11

Completion

2025-11-21

Outcome

Met primary endpoint

release “In Vibrance-2, once-daily alixorexton met the dual primary endpoints” alkermes.com ↗

Drugs

Indications